HUTCHMED (China) Limited
- HCM
- NASDAQ
- Drug Manufacturers - Specialty & Generic
- Oncology/Immunology Biopharma
- Targeted Therapies
$14.15
Today +0.71%Quote Oct 19, 2026, 02:33 PM UTC
+1.66%over the last month
Max drawdown −7.9%From 1-month high −4.0%3 months +24.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$12.34B
Quote Oct 19
Next earnings
Mar 4
Expected, not confirmed
Analyst target
$22.78
+61.0% from here
Floor
$14.12
0.2% below price
Where the price sits
10 analysts
Analyst range, low to high
$13.60$45.00
- Price $14.15
- Resistance $14.29–$14.43
- Consensus $22.78
The price is just above its floor and right under resistance. Analysts' average target sits about 61% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about HCMPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q4 2023 revenue $121.4M
- Collaboration Research And Development$51.7M42.6%
- Other Collaboration Licensing Revenue$28.8M23.7%
- Commercialization Services$23.2M19.1%
- Other Collaboration Royalties Revenue$17.5M14.4%
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,796